Company
Every investor coverage indicates participated in a round SUGEN, Inc. raised.
Companies SUGEN, Inc. acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Julie Cherrington | Vice President of Preclinical and Clinical Research (former) | Brandon BioCatalyst portfolio, Brandon Capital portfolio, GBS Ventures |
Stories naming SUGEN, Inc.. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Biotech company QUE Oncology adds two experienced pharmaceutical executives, Julie Cherrington and Elizabeth Cermak, to its board as it develops a non-hormonal breast cancer therapy.
Clinical-stage biotech QUE Oncology adds two experienced life science executives, Julie Cherrington and Elizabeth Cermak, to its board, while continuing trials of its non-hormonal therapy for breast cancer hot flashes.
Xenome appointed Dr Julie Cherrington, president of San Diego biopharmaceutical Phenomix and a Progen board member, as an independent director of the drug developer, effective 1 August 2009.